Chester County News and Community Website
Headquartered in Berwyn, PA, Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS), a clinical-stage biopharmaceutical company, is set to showcase significant advancements in its treatments for Alzheimer’s disease (AD) and Parkinson’s disease (PD) at the …
Annovis Bio to Present Promising Data on Buntanetap at AD/PD™ 2025 Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has shared its corporate updates and financial results for the fourth quarter and full year of 2024, highlighting significant advancements in its clinical …
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) is set to participate in the 13th Alzheimer’s & Parkinson’s Drug Development Summit, taking place March 18-20 in Boston, Massachusetts. The company will …
Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) will hold a live webcast aimed at providing patients, caregivers, and families with updates on its clinical trials and future plans. The virtual …
Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced that its Chief Executive Officer, Maria Maccecchini, Ph.D., will present at the Oppenheimer’s 35th Annual Healthcare Life Sciences Conference on February …
Annovis Bio CEO to Present at Oppenheimer Healthcare Life Sciences Conference Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has initiated its pivotal Phase 3 clinical trial evaluating buntanetap as a treatment for early Alzheimer’s disease (AD), marking an important step forward …
Annovis Bio Launches Phase 3 Trial for Alzheimer’s Drug Buntanetap Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has announced the completion this week of its underwritten public offering, generating $21 million in gross proceeds. The offering consisted of 5,250,000 shares …
Annovis Bio Raises $21 Million in Public Offering to Advance Alzheimer’s Research Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has revealed plans to conduct an underwritten public offering of common stock and warrants. The company will sell all offered securities directly, with …
Annovis Bio Announces Public Offering of Common Stock and Warrants Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has been granted a U.S. patent for the use of its leading compound, buntanetap, in the treatment and prevention of acute brain and …
Annovis Bio Secures U.S. Patent for Neuroprotective Drug Buntanetap Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced that the U.S. Food and Drug Administration (FDA) has accepted an updated protocol for the company’s pivotal Phase 3 Alzheimer’s (AD) …
FDA Accepts Revised Protocol for Annovis Bio’s Phase 3 Alzheimer’s Study Read More